All Content Outsourced Pharma

  1. Advanced Methodology Of PLGA-Based Parenteral Formulations 5/7/2025

    To enable the development of optimized PLGA-based sustained release formulations, this paper offers essential insights into the polymer’s properties, fabrication techniques, and drug release mechanisms.

  2. Investors Create A U.S. Biotech With GLP-1 Assets From China 5/7/2025

    U.S.-based Kailera Therapeutics formation is a revelatory story highlighting the prowess of today’s investor class. All four of its clinical candidates are GLP-1-based therapies. All were in-licensed from China. Kailera's CTO Doug Bakan fills us in on how it came together, and what's next.

  3. Addressing Human "Error" In Pharma Manufacturing 5/7/2025

    Why is it that managers at pharma manufacturing sites continue to be frustrated by what could be labeled as “avoidable” human errors, and what can companies do about it? Let's investigate.

  4. GeneFab And RegCell Announce Strategic Partnership To Advance Autoimmune Cell Therapy Into U.S. Clinical Trials 5/7/2025

    GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCell, a biotech company advancing regulatory T cell (Treg) therapies for autoimmune diseases.

  5. Bionova Scientific Licenses ATUM's Proprietary Transposon-Based Gene Delivery Technology To Accelerate & De-Risk Cell Line Development 5/7/2025

    Bionova Scientific, an Asahi Kasei boutique commercial-scale biologics contract development and manufacturing organization (CDMO), today announced it has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies.

  6. Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D. 5/6/2025

    In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases.

  7. Vetter Prioritizes Continuity And Action In Its Sustainability Efforts 5/6/2025

    Vetter, a leading global contract development and manufacturing organization (CDMO) published its fourth annual sustainability report. The report shows that the family-owned business is actively pursuing ambitious sustainability goals in climate protection, social responsibility, and business operations in a successful manner.

  8. Proper Care And Handling Of Coupons Used For Swab And Rinse Recovery Studies For Total Organic Carbon Analysis 5/6/2025

    Surrogate surfaces, or “coupons”, are used to simulate pharmaceutical manufacturing surfaces or medical devices for the performance of swab and rinse recovery studies. Experts from The Center for Pharmaceutical Cleaning Innovation provide insights for proper care and handling.

  9. EMA Issues Draft Guideline On Quality Aspects Of mRNA Vaccines 5/6/2025

    The EMA's new draft guideline applies to mRNA vaccines for infectious diseases, providing guidance on manufacturing, characterization, specifications, and more. The deadline for public comments is Sept. 30, 2025.

  10. Almac Discovery And Formosa Pharmaceuticals Announce Global Licensing Agreement For Development And Commercialisation Of ALM-401, A First-In-Class EGFRxROR1 Bispecific Antibody-Drug Conjugate 5/6/2025

    Formosa Pharmaceuticals, Inc. and Almac Discovery announce a global licensing agreement for development and commercialisation of ALM-401, a first-in-class engineered bispecific Antibody-Drug Conjugate (ADC), addressing the high unmet needs of cancer patients worldwide suffering with intractable and aggressive solid tumours.